Mixed results with enzalutamide in non-metastatic prostate cancer
Enzalutamide failed to deliver in high-risk localised prostate cancer, but improved survival, in combination with leuprolide, in biochemically recurrent prostate cancer
Harnessing Large Language Models in oncology: ESMO’s framework for integration in the clinic
The ELCAP statements, developed by a group of international experts, help oncology stakeholders recognise the opportunities and the risks of these artificial intelligence systems by categorising them into three types
Survival benefits demonstrated with immunochemotherapy in platinum-resistant ovarian cancer
The ENGOT-ov65/KEYNOTE-B96 trial reported small but clinically relevant progression-free survival increments and significantly improved overall survival in platinum-resistant ovarian cancer
Preventing cancer recurrence with novel antibody–drug conjugates
Presidential presentations in early breast cancer provide first evidence of ADCs rapidly moving into the curative setting across multiple cancer types
Peri-operative enfortumab vedotin plus pembrolizumab prolongs survival in muscle-invasive bladder cancer
In KEYNOTE-905/EV-303, the combination of an antibody–drug conjugate and immunotherapy showed statistically significant and clinically meaningful improvements in event-free survival and overall survival
Trastuzumab deruxtecan is moving to the curative setting in early HER2-positive breast cancer
Positive findings from the DESTINY-Breast05 and DESTINY-Breast11 trials suggest that a paradigm change in the treatment of high-risk patients may be imminent
Head and neck cancers: should research continue to invest in immunotherapy?
Despite growing disappointing results from clinical trials, focus should now turn to the design of studies to better reflect tumour heterogeneity
Is thymic health a novel tumour-agnostic biomarker?
Study findings reveal that good thymic health, based on an AI-derived algorithm, is associated with improved survival after immunotherapy in different tumour types
Extensive-stage small-cell lung cancer: new approaches on the horizon?
Tarlatamab as first-line therapy and ceralasertib plus durvalumab as maintenance therapy have demonstrated potential efficacy and manageable tolerability
What is the clinical value of genomic profiling in rare cancers?
Early studies investigated the potential of genomic profiling, but prospective and comprehensive data are required to support wider implementation